Participant characteristics with regards to MRD
| . | MRD negative before and after HCT (n = 167) . | MRD positive before and after HCT (n = 174) . | MRD positive after HCT (n = 71) . | Multiclonal FLT3-ITD mutations before and after HCT (n = 54) . |
|---|---|---|---|---|
| Age, median, y | 53 | 53 | 52 | 52.5 |
| Female, n (%) | 89 (53.3) | 75 (43.1) | 33 (46.5) | 23 (42.6) |
| Karyotype, n (%) | ||||
| Favorable | 3 (1.8) | 9 (5.2) | 6 (8.5) | 2 (3.7) |
| Intermediate | 159 (95.2) | 157 (5.2) | 63 (88.7) | 49 (90.7) |
| Adverse | 5 (3.0) | 8 (4.6) | 2 (2.8) | 3 (5.6) |
| NPM1mut, n (%) | 66 (39.5) | 51 (29.3) | 24 (33.8) | 14 (25.9) |
| Median ITD length bp (range) | — | 45 (6-235) | 45 (15-183) | 48 (15-165) |
| VAF, median (VAF/clone) | — | 2.47 × 10–5 | 1.37 × 10–5 | 2.35 × 10–5 |
| VAF, median VAF/pt | — | 4.7 × 10–5 | 1.73 × 10–5 | 1.2 × 10–4 |
| VAF, range | — | 1.09 × 10–6 to 3 × 10–1 | 2.16 × 10–6 to 3 × 10–1 | 2.16 × 10–6 to 3 × 10–1 |
| Conditioning, n (%) | ||||
| MAC | 96 (57.5) | 107 (61.5) | 44 (62) | 31 (57.4) |
| RIC | 71 (42.5) | 67 (38.5) | 27 (38) | 23 (42.6) |
| Courses chemotherapy before HCT, mean; median | 2.9; 3 | 2.5; 2 | 2.5; 2 | 2.3; 2 |
| Days from AML diagnosis to HCT, mean; median | 157; 143 | 137; 127 | 135; 121 | 125; 118 |
| FLT3 inhibitor used before HCT, n (%) | 97 (58.1) | 106 (60.9) | 36 (50.7) | 29 (53.7) |
| . | MRD negative before and after HCT (n = 167) . | MRD positive before and after HCT (n = 174) . | MRD positive after HCT (n = 71) . | Multiclonal FLT3-ITD mutations before and after HCT (n = 54) . |
|---|---|---|---|---|
| Age, median, y | 53 | 53 | 52 | 52.5 |
| Female, n (%) | 89 (53.3) | 75 (43.1) | 33 (46.5) | 23 (42.6) |
| Karyotype, n (%) | ||||
| Favorable | 3 (1.8) | 9 (5.2) | 6 (8.5) | 2 (3.7) |
| Intermediate | 159 (95.2) | 157 (5.2) | 63 (88.7) | 49 (90.7) |
| Adverse | 5 (3.0) | 8 (4.6) | 2 (2.8) | 3 (5.6) |
| NPM1mut, n (%) | 66 (39.5) | 51 (29.3) | 24 (33.8) | 14 (25.9) |
| Median ITD length bp (range) | — | 45 (6-235) | 45 (15-183) | 48 (15-165) |
| VAF, median (VAF/clone) | — | 2.47 × 10–5 | 1.37 × 10–5 | 2.35 × 10–5 |
| VAF, median VAF/pt | — | 4.7 × 10–5 | 1.73 × 10–5 | 1.2 × 10–4 |
| VAF, range | — | 1.09 × 10–6 to 3 × 10–1 | 2.16 × 10–6 to 3 × 10–1 | 2.16 × 10–6 to 3 × 10–1 |
| Conditioning, n (%) | ||||
| MAC | 96 (57.5) | 107 (61.5) | 44 (62) | 31 (57.4) |
| RIC | 71 (42.5) | 67 (38.5) | 27 (38) | 23 (42.6) |
| Courses chemotherapy before HCT, mean; median | 2.9; 3 | 2.5; 2 | 2.5; 2 | 2.3; 2 |
| Days from AML diagnosis to HCT, mean; median | 157; 143 | 137; 127 | 135; 121 | 125; 118 |
| FLT3 inhibitor used before HCT, n (%) | 97 (58.1) | 106 (60.9) | 36 (50.7) | 29 (53.7) |
bp, base pair; MAC, myeloablative conditioning; NPM1mut, NPM1 mutation; pt, participant; RIC, reduced-intensity conditioning.